Evidence map›Paper›PMID 32879363›Full record

ArticleScientific reports2020

Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines.

Julio M Rios De La Rosa, Alice Spadea, Roberto Donno, Enrique Lallana, Yu Lu, Sanyogitta Puri, Patrick Caswell, M Jayne Lawrence, Marianne Ashford, Nicola Tirelli

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Organelle-Targeting Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Julio M Rios De La RosaNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK. juliomanuel.riosdelarosa@manchester.ac.uk.
Alice SpadeaNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Roberto DonnoNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Enrique LallanaNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Yu LuNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Sanyogitta PuriAdvanced Drug Delivery, Pharmaceutical Sciences, R & D, AstraZeneca, Cambridge, UK.
Patrick CaswellWellcome Trust Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, UK.
M Jayne LawrenceNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Marianne AshfordAdvanced Drug Delivery, Pharmaceutical Sciences, R & D, AstraZeneca, Macclesfield, UK.
Nicola TirelliNorth West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK. nicola.tirelli@iit.it.
University of Manchester · GBAstraZeneca (United Kingdom) · GBItalian Institute of Technology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study is about fine tuning the targeting capacity of peptide-decorated nanoparticles to discriminate between cells that express different integrin make-ups. Using microfluidic-assisted nanoprecipitation, we have prepared poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles with a PEGylated surface decorated with two different arginine-glycine-aspartic acid (RGD) peptides: one is cyclic (RGDFC) and has specific affinity towards α

Indexed as

OligopeptidesCell Line, TumorDrug Delivery SystemsFemaleGliomaHumansIntegrinsLinear ModelsMagnetic Resonance SpectroscopyMicrofluidicsMicroscopy, ConfocalMicroscopy, FluorescenceNanoparticlesNeoplasmsOvarian NeoplasmsPoloxamerarginyl-glycyl-aspartic acidIntegrinsOligopeptidesPoloxamerPolylactic Acid-Polyglycolic Acid CopolymerRhodamines

Identifiers

PMID32879363
PMCPMC7468293
OpenAlexW3081687173

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.